Raymond James Launches MeiraGTx Coverage with Strong Buy Rating
Raymond James initiates MeiraGTx with Strong Buy rating and $29 price target, highlighting company's manufacturing platform and two major commercial opportunities in xerostomia and Parkinson's disease.